Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526746 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function
A Phase 1 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01526746 is a Phase 1 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT01526746, a Phase 1 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelteon will also be assessed throughout this study.
Interventions
- DRUG Tasimelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526746
The ClinicalTrials.gov registry entry for NCT01526746 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tasimelteon is the first listed.
NCT01526746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01526746 about?
NCT01526746 is a clinical study titled "Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function". The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelt...
What is the current status of trial NCT01526746?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01526746?
The interventions under investigation include: Tasimelteon (DRUG).
Who is sponsoring clinical trial NCT01526746?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.